Maravai LifeSciences (MRVI) Competitors $2.73 -0.16 (-5.54%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.74 +0.00 (+0.18%) As of 07/11/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. XENE, GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, and DNLIShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Its Competitors Xenon Pharmaceuticals Gemini Therapeutics ImmunityBio Twist Bioscience Arrowhead Pharmaceuticals Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Denali Therapeutics Xenon Pharmaceuticals (NASDAQ:XENE) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Which has more volatility & risk, XENE or MRVI? Xenon Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Do insiders & institutionals have more ownership in XENE or MRVI? 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer XENE or MRVI? Xenon Pharmaceuticals presently has a consensus target price of $54.82, indicating a potential upside of 70.19%. Maravai LifeSciences has a consensus target price of $6.64, indicating a potential upside of 143.18%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media refer more to XENE or MRVI? In the previous week, Maravai LifeSciences had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 9 mentions for Maravai LifeSciences and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.85 beat Maravai LifeSciences' score of 0.69 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is XENE or MRVI more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -32.44% -30.84% Maravai LifeSciences -67.14%-12.91%-6.87% Which has stronger valuation & earnings, XENE or MRVI? Maravai LifeSciences has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M262.09-$234.33M-$3.23-9.97Maravai LifeSciences$259.18M2.68-$144.85M-$1.14-2.39 SummaryXenon Pharmaceuticals and Maravai LifeSciences tied by winning 8 of the 16 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$735.97M$10.60B$5.61B$9.11BDividend YieldN/A2.07%5.24%4.01%P/E Ratio-2.3916.2727.9620.25Price / Sales2.6830.15430.8999.65Price / Cash4.6822.9637.4658.16Price / Book1.203.668.045.49Net Income-$144.85M$235.43M$3.18B$250.27M7 Day Performance-1.41%1.27%3.67%4.80%1 Month Performance20.80%2.95%4.09%7.68%1 Year Performance-69.46%-15.74%29.58%16.36% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences3.4888 of 5 stars$2.73-5.5%$6.64+143.2%-68.3%$735.97M$259.18M-2.39610Options VolumeXENEXenon Pharmaceuticals3.582 of 5 stars$31.30-3.4%$54.82+75.1%-21.8%$2.40B$7.50M-9.69210News CoverageOptions VolumeGMTXGemini TherapeuticsN/A$54.50+0.7%N/A+26.6%$2.36BN/A-54.5030High Trading VolumeIBRXImmunityBio2.3458 of 5 stars$2.64-2.2%$12.25+364.0%-58.1%$2.33B$14.74M-4.55590Analyst ForecastTWSTTwist Bioscience4.3756 of 5 stars$36.79+2.4%$50.40+37.0%-27.5%$2.20B$312.97M-11.32990Gap DownARWRArrowhead Pharmaceuticals3.5778 of 5 stars$15.80-1.7%$43.71+176.7%-35.2%$2.18B$3.55M-11.29400Gap DownAPLSApellis Pharmaceuticals4.2339 of 5 stars$17.31-0.7%$40.05+131.4%-50.0%$2.18B$781.37M-9.67770VCELVericel3.7051 of 5 stars$42.55+2.0%$61.14+43.7%-19.2%$2.14B$237.22M1,418.81300Positive NewsRXRXRecursion Pharmaceuticals2.1298 of 5 stars$5.06+0.6%$7.00+38.3%-31.3%$2.06B$58.84M-2.86400Analyst ForecastOptions VolumeGap DownNAMSNewAmsterdam Pharma2.6978 of 5 stars$18.11-2.5%$42.89+136.8%+2.6%$2.03B$45.56M-9.634DNLIDenali Therapeutics4.6375 of 5 stars$13.99-0.8%$33.71+141.0%-37.1%$2.03BN/A-5.24430News CoveragePositive NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies XENE Alternatives GMTX Alternatives IBRX Alternatives TWST Alternatives ARWR Alternatives APLS Alternatives VCEL Alternatives RXRX Alternatives NAMS Alternatives DNLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
